Trial Profile
A Phase 3, Randomized, Two-Arm, Open-Label, Multicenter, International Trial of Alisertib (MLN8237) or Investigator's Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Apr 2022
Price :
$35
*
At a glance
- Drugs Alisertib (Primary) ; Gemcitabine; Pralatrexate; Romidepsin
- Indications Peripheral T-cell lymphoma
- Focus Registrational; Therapeutic Use
- Acronyms LUMIERE
- Sponsors Takeda Oncology
- 01 Feb 2019 Results evaluating the efficacy of alisertib, an investigational Aurora A kinase inhibitor, in patients with relapsed/refractory peripheral T-cell lymphoma, published in the Journal of Clinical Oncology.
- 25 Apr 2018 This trial has been completed in Hungary (2017-12-18) , according to European Clinical Trials Database
- 24 Apr 2018 Status changed from active, no longer recruiting to completed.